Wockhardt Limited Asset Resilience Ratio
Wockhardt Limited asset resilience ratio. Wockhardt Limited (WOCKPHARMA) has an Asset Resilience Ratio of 5.19% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See WOCKPHARMA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Wockhardt Limited (2005–2025)
Asset resilience ratio of Wockhardt Limited from 2005 to 2025. This chart shows how Wockhardt Limited's Asset Resilience Ratio has changed over time. Read Wockhardt Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Wockhardt Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Wockhardt Limited's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs4.22 Billion | 5.19% |
| Total Liquid Assets | Rs4.22 Billion | 5.19% |
Asset Resilience Insights
- Limited Liquidity: Wockhardt Limited maintains only 5.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wockhardt Limited Industry Peers by Asset Resilience Ratio
Compare Wockhardt Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Wockhardt Limited Asset Resilience Ratio by Year (2005–2025)
Wockhardt Limited asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Wockhardt Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 5.19% | Rs4.22 Billion ≈ $45.64 Million |
Rs81.35 Billion ≈ $879.77 Million |
+4.98pp |
| 2024-03-31 | 0.21% | Rs160.00 Million ≈ $1.73 Million |
Rs76.49 Billion ≈ $827.21 Million |
-1.01pp |
| 2023-03-31 | 1.22% | Rs940.00 Million ≈ $10.17 Million |
Rs76.83 Billion ≈ $830.89 Million |
+1.11pp |
| 2022-03-31 | 0.11% | Rs90.00 Million ≈ $973.32K |
Rs82.43 Billion ≈ $891.45 Million |
+0.04pp |
| 2021-03-31 | 0.07% | Rs54.40 Million ≈ $588.32K |
Rs77.73 Billion ≈ $840.59 Million |
-0.49pp |
| 2020-03-31 | 0.56% | Rs457.30 Million ≈ $4.95 Million |
Rs81.79 Billion ≈ $884.52 Million |
-0.92pp |
| 2019-03-31 | 1.48% | Rs1.16 Billion ≈ $12.54 Million |
Rs78.31 Billion ≈ $846.90 Million |
-3.42pp |
| 2018-03-31 | 4.90% | Rs4.00 Billion ≈ $43.26 Million |
Rs81.62 Billion ≈ $882.69 Million |
-13.38pp |
| 2017-03-31 | 18.28% | Rs16.39 Billion ≈ $177.29 Million |
Rs89.69 Billion ≈ $969.93 Million |
+8.10pp |
| 2016-03-31 | 10.18% | Rs8.10 Billion ≈ $87.56 Million |
Rs79.52 Billion ≈ $860.00 Million |
+4.34pp |
| 2015-03-31 | 5.85% | Rs4.06 Billion ≈ $43.87 Million |
Rs69.39 Billion ≈ $750.41 Million |
-3.13pp |
| 2014-03-31 | 8.97% | Rs5.94 Billion ≈ $64.26 Million |
Rs66.22 Billion ≈ $716.15 Million |
+8.97pp |
| 2013-03-31 | 0.00% | Rs2.70 Million ≈ $29.20K |
Rs60.40 Billion ≈ $653.21 Million |
-4.60pp |
| 2011-03-31 | 4.61% | Rs2.71 Billion ≈ $29.34 Million |
Rs58.89 Billion ≈ $636.83 Million |
-3.87pp |
| 2010-03-31 | 8.48% | Rs4.85 Billion ≈ $52.50 Million |
Rs57.26 Billion ≈ $619.21 Million |
-0.89pp |
| 2009-03-31 | 9.37% | Rs6.31 Billion ≈ $68.20 Million |
Rs67.28 Billion ≈ $727.62 Million |
+5.71pp |
| 2008-03-31 | 3.66% | Rs1.89 Billion ≈ $20.42 Million |
Rs51.53 Billion ≈ $557.29 Million |
-33.74pp |
| 2005-03-31 | 37.41% | Rs7.18 Billion ≈ $77.63 Million |
Rs19.19 Billion ≈ $207.51 Million |
-- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more